Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.60 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.52 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21765914 | 0.84 | CHRNB2 (0.72) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL21765915 | 0.84 | CHRNB2 (0.72) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL15932468 | 0.80 | CHRNB2 (0.67) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL11773423 | 0.77 | CHRNB2 (0.62) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL18498281 | 0.77 | CHRNB2 (0.62) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL23343819 | 0.77 | CHRNB2 (0.62) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL20343593 | 0.77 | CHRNB2 (0.62) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL1462657 | 0.75 | CHRNA4 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL3405917 | 0.75 | CHRNA4 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL25075300 | 0.75 | CHRNB2 (0.60) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714018-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-20070117859-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-05-24 | — | — | US | disclosed |
| US-7164019-B2 | Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC | ROCHE PALO ALTO LLC (US) | 2007-01-16 | — | — | US | disclosed |
| US-20060014767-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014767-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | CHRNB2 2902/4885CHRNA3 1232/4885CHRNA4 2114/4885 |
| US-20070117859-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | CHRNB2 2902/4885CHRNA3 1232/4885CHRNA4 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.